AMGEN Inc

Research AMGEN Inc (AMGN) on Bullrun: valuation model: 6.9% undervalued, market cap USD 194.59B, P/E 25.1, dividend yield 2.7%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerAMGN
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryDrug Manufacturers-General
• CurrencyUSD
• Valuation signal6.9% undervalued
• Market capUSD 194.59B
• P/E25.1
• Dividend yield2.7%
• Financial periodFY2025
• RevenueUSD 36.75B
• Revenue growth10.0%
• Net incomeUSD 7.71B
• Free cash flowUSD 8.10B
• Gross margin67.2%

Valuation Snapshot

Bullrun's latest valuation model marks AMGEN Inc as 6.9% undervalued; latest market cap is USD 194.59B; P/E is 25.1; dividend yield is 2.7%.

About AMGEN Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention;

Frequently asked questions

Is AMGEN Inc overvalued or undervalued?

Bullrun's valuation model currently marks AMGEN Inc as 6.9% undervalued.

What is AMGEN Inc's market cap?

AMGEN Inc's market capitalization is USD 194.59B.

What is AMGEN Inc's P/E ratio?

AMGEN Inc's price-to-earnings (P/E) ratio is 25.1.

Does AMGEN Inc pay a dividend?

AMGEN Inc has a dividend yield of 2.7%.

What does AMGEN Inc do?

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis;